Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.58 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.58 |
| ▸ | CLK2 | P49760 | 1/20 | 0.58 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.58 |
| ▸ | CCNC | P24863 | 6/20 | 0.46 |
| ▸ | CDK8 | P49336 | 6/20 | 0.46 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 6/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7683073 | 0.84 | SMN1; SMN2 (0.51) | CSNK1A1CSNK1DCLK2CSNK1G1HASPIN | |
| SCHEMBL17342913 | 0.81 | RAB9A (0.42) | CSNK1A1CSNK1DCLK2CSNK1G1BRPF1 | |
| SCHEMBL7742019 | 0.81 | CSNK1A1 (0.45) | CSNK1A1CSNK1DCLK2CSNK1G1CCNC | |
| SCHEMBL7685369 | 0.74 | CSNK1A1 (1.00) | CSNK1A1CSNK1DCLK2CSNK1G1CCNC | |
| Hydrochloric Acid SCHEMBL7742023 | 0.71 | CSNK1A1 (0.93) | CSNK1A1CSNK1DCLK2CSNK1G1CCNC | |
| SCHEMBL7687649 | 0.71 | CSNK1A1 (0.81) | CSNK1A1CSNK1DCLK2CSNK1G1CCNC | |
| SCHEMBL6803837 | 0.69 | MAPT (0.51) | CSNK1A1CSNK1DCLK2CSNK1G1CCNC | |
| SCHEMBL22258783 | 0.69 | CSNK1A1 (0.42) | CSNK1A1CSNK1DCLK2CSNK1G1CCNC | |
| SCHEMBL1395221 | 0.69 | ALDH1A1 (0.46) | CSNK1A1CSNK1DCLK2CSNK1G1CCNC | |
| SCHEMBL7681361 | 0.69 | CSNK1D (0.88) | CSNK1A1CSNK1DCLK2CSNK1G1CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417202-B1 | 3-ACETYL-4-METHYL-2,5-DI(4-PYRIDYL)-1H-PYRROLE, FOR EXAMPLE; TREATING CELL ADHESION MOLECULES (CAMS) MEDIATED DISEASES SUCH AS ARTHRITIS, AIDS, SEPTIC SHOCK, CACHEXIA, TRANSPLANT REJECTION | PFIZER INC. | 2002-07-09 | — | — | US | disclosed |
| US-20020049235-A1 | 3-acetyl-4-methyl-2,5-di(4-pyridyl)-1H-pyrrole, for example; treating cell adhesion molecules (CAMs) mediated diseases such as arthritis, AIDS, septic shock, cachexia, transplant rejection | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049235-A1 | 3-acetyl-4-methyl-2,5-di(4-pyridyl)-1H-pyrrole, for example; treating cell adhesion molecules (CAMs) mediated diseases such as arthritis, AIDS, septic shock, cachexia, transplant rejection | ICAM1, VCAM1, CD14 | CSNK1A1 2321/4885CSNK1D 2460/4885CLK2 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.